A new CEO has been appointed by the Royal National Orthopaedic Hospital, who will also lead the trust as it becomes part of the elective accelerator programme to tackle waiting lists.
Professor Paul Fish has acted as interim CEO throughout the pandemic, following previous CEO Rob Hurd who left the trust to become a system leader in the North Central London area.
Professor Paul Fish said of his appointment: “I am both delighted and honoured to have been appointed Chief Executive of the RNOH. The work that you do personally and we do collectively as a trust is critical work for the NHS. Over the coming years, I want us to grow, to extend the reach of our influence and leadership in musculoskeletal medicine, to become more sustainable as an organisation and, most importantly, to be able to improve the lives of ever greater numbers of patients.”
In May, the trust announced it would be part of the ‘elective accelerator system’ to tackle long waiting lists. The trust is a part of the North Central London ICS and has a target of delivering 120% of its pre-pandemic services before the end of July.
Lucy Davies, RNOH Chief Operating Officer, said: “We are really pleased at RNOH to have the opportunity to treat more patients via the accelerator programme. This will help us to address increased clinical urgency and longer waits resulting from the pandemic. We are planning to treat additional children and adults in outpatients, diagnostics, day case and inpatient settings.”
Professor Paul Fish will formally being his role immediately and will start the recruitment process for a new chief nurse at the trust.
